Upadacitinib for treating moderately to severely active ulcerative colitis
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Commercial arrangement
There is a simple discount patient access scheme for upadacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. ...